<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01679860</url>
  </required_header>
  <id_info>
    <org_study_id>PTCL-062006-004234-33</org_study_id>
    <nct_id>NCT01679860</nct_id>
  </id_info>
  <brief_title>Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma</brief_title>
  <acronym>PTCL-06</acronym>
  <official_title>Intensive Chemo-immunotherapy as First-line Treatment in Adult Patients With Peripheral T-cell Lymphoma (PTCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Peripheral T cell lymphomas (PTCL) are a rare hematologic disease. Five-year overall survival&#xD;
      (OS) of PTCL patients (pts) ranges between 20 and 30%. Allogeneic stem cell transplantation&#xD;
      (allo-STC) may have a curative role for these pts but its toxicity is high when myeloablative&#xD;
      conditioning is used. Reduced intensity conditionings (RIC) can decrease transplant related&#xD;
      toxicity and mortality. The investigators have recently proved feasibility and potential&#xD;
      efficacy of a RIC regimen in relapsed PTCL patients.&#xD;
&#xD;
      We want to investigate whether it is possible to improve the outcome of alk negative PTCL&#xD;
      pts, stage II-IV at diagnosis, by intensifying the therapeutic approach.&#xD;
&#xD;
      The intensification will be obtained by combining intensive chemotherapy, alemtuzumab&#xD;
      (anti-CD52 humanised antibody) and auto- or allo-SCT in pts aged between 18 and 60 years&#xD;
      (Clinical Study A) or adding alemtuzumab to standard chemotherapy (CHOP) in pts aged between&#xD;
      61 and 70 years(Clinical Study B).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion criteria Clin A&#xD;
&#xD;
        -  Age ≥18 &lt; or =60 years (patients older than 60 years are excluded because of the&#xD;
           intensive chemotherapy and transplant procedures)&#xD;
&#xD;
        -  Histologically proven diagnosis of PTCL, including the following categories: PTCL-U&#xD;
           (peripheral T-cell lymphoma, unspecified), AILD-T (angioimmunoblastic-like T-cell&#xD;
           lymphoma), ALKneg ALCL (ALK-negative anaplastic large cell lymphoma),intestinal T - NHL&#xD;
&#xD;
        -  Advanced stage disease (stage II-IV) or stage I and aaIPI score ≥ 2&#xD;
&#xD;
        -  Written informed consent&#xD;
&#xD;
      Inclusion criteria Clin B&#xD;
&#xD;
        -  Age &gt;60 and ≤75 years (patients older than 75 years are excluded because of the&#xD;
           intensive chemo-immunotherapy program)&#xD;
&#xD;
        -  Histological proven diagnosis of PTCL, including the following categories: PTCL-U&#xD;
           (peripheral T-cell lymphoma, unspecified), AILD-T (angioimmunoblastic-like T-cell&#xD;
           lymphoma), ALKneg ALCL (ALK-negative anaplastic large cell lymphoma), intestinal T - NHL&#xD;
&#xD;
        -  Advanced-stage disease (stage II-IV) or stage I and aaIPI score ≥ 2&#xD;
&#xD;
        -  Informed written consent&#xD;
&#xD;
      In clinical study A (Clin A) we are planning to evaluate the efficacy and the feasibility of&#xD;
      an intensified chemo-immunotherapy program including auto-SCT or RIC allo-SCT in advanced&#xD;
      stage PTCL pts ≥ 18 and &lt; or = 60 years.&#xD;
&#xD;
      In clinical study B (Clin B) we intend to verify the efficacy and the feasibility of a&#xD;
      combined immuno-chemotherapy approach in a subset of elderly pts aged &gt; 60 and &lt; or = 75&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>one year</time_frame>
    <description>number of clinical responses</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>evaluation of OS (overall survival)</measure>
    <time_frame>4 years</time_frame>
    <description>OS time is calculated from patients enrollment to death for all causes; censored cases are pts alive at the date of last follow-up assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DFS (Disease Free Survival)</measure>
    <time_frame>4 years</time_frame>
    <description>DFS time is the interval between CR achievement and the first disease relapse or death regardless of the cause.Definition of disease response/progression will be performed according to the criteria published by Juweid et al.(J Clin Oncol. 2005; 23: 4652-61)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TRM (Treatment Related Mortality)</measure>
    <time_frame>4 years</time_frame>
    <description>TRM will be analysed by computing the corresponding crude cumulative incidence curve, considering disease-related death as competing event.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Lymphoma, T-Cell, Peripheral</condition>
  <arm_group>
    <arm_group_label>Clin A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clin A. CHOP-Campath (CHOP-C) for 2 cycles , Hyper-C-Hidam for 2 cycles and auto-SCT (stem cell transplantation) or RIC allo-SCT in advanced stage PTCL pts ≥ 18 and ≤ 60 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clin B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clin B: CHOP-Campath (CHOP-C) for 6 cycles . It is a combined immunochemotherapy approach in a subset of elderly pts aged &gt; 60 ≤ 75 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Clin A. CHOP-CAMPATH (Chemo-immunotherapy) + SCT</intervention_name>
    <description>Clin A:&#xD;
CHOP-Campath (CHOP-C) for 2 cycles (every 21 days): Doxorubicin 50mg/m2 day +1, Vincristin 1.4mg/m2 day +1, Cyclophosphamide 750mg/m2 day +1, prednisone 100mg/m2 PO on days +1 to +5; Campath-1H (alemtuzumab) dose escalation 3-10-20mg IV days - 2, - 1, 0 (first CHOP-C) or 30mg SC day 0 (second CHOP-C). Methotrexate 12.5mg IT, Ara-C 40mg IT, Dexamethasone 4mg IT on days + 1 and 21 (first and second CHOP-C).&#xD;
HYPER-C-HiDAM for 2 cycles: Methotrexate 1.5gr/m2 day +1; Cyclophosphamide 300mg/m2 every 12 hours days +2-3-4; ARA-C 2gr/m2 every 12 hours days +2-3-4; G-CSF 5μcg/kg/day starting from day +5 until peripheral blood stem cell harvest&#xD;
Myeloablative regimen followed by autologous transplantation or Reduced intensity conditioning followed by allogeneic transplantation.</description>
    <arm_group_label>Clin A</arm_group_label>
    <other_name>Mab - Campath (Alemtuzumab)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clin B (CHOP- CAMPATH) Chemo-immunotherapy</intervention_name>
    <description>Clin B:&#xD;
CHOP-Campath (CHOP-C) for 6 cycles (every 21 days): Doxorubicin 50mg/m2 day +1, Vincristin 1.4mg/m2 day +1, Cyclophosphamide 750mg/m2 day +1, prednisone 100mg/m2 PO from day +1 to day +5¸ Campath-1H (alemtuzumab) 3-10mg IV on days - 1 and 0 ( first CHOP-C course) or 10mg SC on day 0 (for the following 5 C-CHOP courses). Methotrexate 12.5mg IT, Ara-C 40mg IT, Dexamethasone 4mg IT on day +1 of each CHOP-C course.</description>
    <arm_group_label>Clin B</arm_group_label>
    <other_name>Mab- Campath (Alemtuzumab)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 &lt;60 years (patients older than 60 years are excluded because of the intensive&#xD;
             chemotherapy and transplant procedures)&#xD;
&#xD;
          -  Histologically proven diagnosis of PTCL, including the following categories: PTCL-U&#xD;
             (peripheral T-cell lymphoma, unspecified), AILD-T (angioimmunoblastic-like T-cell&#xD;
             lymphoma), ALKneg ALCL (ALK-negative anaplastic large cell lymphoma),intestinal T -&#xD;
             NHL&#xD;
&#xD;
          -  Advanced stage disease (stage II-IV) or stage I and aaIPI score ≥ 2&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Histological PTCL subset other than PTCL-U, AILD-T ALCL-ALKneg, intestinal T - NHL&#xD;
&#xD;
          -  Central nervous system localization&#xD;
&#xD;
          -  Positive serologic markers for human immunodeficiency virus (HIV), hepatitis B virus&#xD;
             (HBV), and hepatitis C virus (HCV) infection&#xD;
&#xD;
          -  Serum bilirubin levels &gt; 2 the upper normal limit&#xD;
&#xD;
          -  Clearance of creatinine &lt; 50 ml/min&#xD;
&#xD;
          -  DLCO &lt; 50%&#xD;
&#xD;
          -  Ejection fraction &lt; 45% (or myocardial infarction in the last 12 months)&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Patient not agreeing to take adequate contraceptive measures during the study&#xD;
&#xD;
          -  Psychiatric disease&#xD;
&#xD;
          -  Any active, uncontrolled infection&#xD;
&#xD;
          -  Type I hypersensitivity or anaphylactic reactions to proteins drugs&#xD;
&#xD;
          -  Active secondary malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>paolo corradini</last_name>
    <role>Principal Investigator</role>
    <affiliation>fondazione IRCCS istituto nazionale tumori Milano</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Luigi</name>
      <address>
        <city>Orbassano</city>
        <state>Torino</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale SS. Antonio e Biagio e Cesare Arrigo</name>
      <address>
        <city>Alessandria</city>
        <zip>15100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ancona - Division of Hematology</name>
      <address>
        <city>Ancona</city>
        <zip>62020</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Riuniti, Bergamo - Division of Hematology</name>
      <address>
        <city>Bergamo</city>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Generale Regionale Bolzano</name>
      <address>
        <city>Bolzano</city>
        <zip>39100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedale Vittorio Emanuele Ferrarorro S. Bambino- Università di Catania</name>
      <address>
        <city>Catania</city>
        <zip>94124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Croce - Division of Hematology</name>
      <address>
        <city>Cuneo</city>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Maggiore Policlinico di Milano</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele, Milano - Division of Hematology</name>
      <address>
        <city>Milan</city>
        <zip>20100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Hematology - Fondazione IRCCS Istituto Nazionale Tumori</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Cervello - Bone Marrow Transplantation Unit</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Carlo</name>
      <address>
        <city>Potenza</city>
        <zip>85100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda OspedalieraSan Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università di Torino- Azienda Ospedaliera S. Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Udine</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Policlinico di Verona</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>August 30, 2012</study_first_submitted>
  <study_first_submitted_qc>September 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2012</study_first_posted>
  <last_update_submitted>September 3, 2012</last_update_submitted>
  <last_update_submitted_qc>September 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</investigator_affiliation>
    <investigator_full_name>Paolo Corradini</investigator_full_name>
    <investigator_title>Director Hematology and BMT Unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Immunologic Factors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

